טוען...
A Bayesian Adaptive Design for Cancer Phase I Trials Using a Flexible Range of Doses
We present a Bayesian adaptive design for dose finding in cancer phase I clinical trials. The goal is to estimate the maximum tolerated dose (MTD) after possible modification of the dose range during the trial. Parametric models are used to describe the relationship between the dose and the probabil...
שמור ב:
| הוצא לאור ב: | J Biopharm Stat |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5832533/ https://ncbi.nlm.nih.gov/pubmed/28858566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10543406.2017.1372774 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|